CBD And Nicotine Formula To Treat Smokeless Tobacco Addiction Receives Patent From Japan, FDA Approval Next

CV Sciences, Inc. CVSI received a formal certificate of grant from the Japan Patent Office for its patent application 7216697.

The patent covers methods for treating smokeless tobacco addiction by administering pharmaceutical formulations containing CBD and nicotine. CV Sciences has also filed corresponding patent applications that provide similar patent protection in additional key markets, with patents already granted in the United States, Canada, Australia, Germany, Great Britain, France, Spain, Netherlands and Italy.

“The worldwide market for smokeless tobacco addiction is a multi-billion dollar sector, providing a life-changing treatment to people around the world,” stated Joseph Dowling, CEO of CV Sciences. “CV Sciences’ developmental efforts surrounding CBD and nicotine have the potential to alter healthcare with a safe, natural method to reducing addiction to harmful substances. Japan Patent Office’s patent grant further validates our first-of-its-kind treatment and positions the company to meet the medical needs of millions of patients globally.”

CV Sciences’ initial drug candidate (CVSI-007) contains nicotine and CBD to support the cessation of smokeless tobacco use and addiction. With the Japan Patent Office’s formal grant of the patent, the company will further development efforts and continue to seek approval from the Food and Drug Administration (FDA) to commercialize the world’s first and only FDA-approved treatment for smokeless tobacco addiction.

Smokeless tobacco such as chewing tobacco, moist snuff or inhaled through the nose,  contains nicotine and many harmful, cancer-causing chemicals. Using it can lead to nicotine addiction and can cause cancers of the mouth, esophagus and pancreas, says the National Cancer Institute. It may also cause heart disease, gum disease, and other health problems.

Benzinga's Cannabis Capital Conference Is Back

The most successful cannabis business event in the world, the Benzinga Cannabis Capital Conference, returns to Miami for its 16th edition. This is the place where DEALS GET DONE, where money is raised, M&A starts, and companies meet investors and key partners. Join us at the Fontainebleau Miami Beach Hotel in Florida on April 11-12. Don’t miss out. Secure your tickets now. Prices will surge very soon.

Photo: Benzinga edit with photos by Matthias Zomer on Pexels, squarefrog on Pixabay